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Asymptomatic Left Bundle Branch Block Predicts 
New-Onset Congestive Heart Failure and Death 
From Cardiovascular Diseases
Peyman N. Azadania, Ata Soleimanirahbarb, Gregory M. Marcusb, Thaddeus J. Haightc, 
Milton Hollenbergb, Jeffrey E. Olginb, Byron K. Leeb, d
Abstract
Background: Left bundle branch block (LBBB) has been pro-
posed as a risk factor for cardiovascular morbidity and mortality. 
We sought to characterize the strength of these associations in a 
population without preexisting clinical heart disease.
Methods: The association between LBBB and new-onset conges-
tive heart failure (CHF) or death from cardiovascular diseases was 
examined in 1,688 participants enrolled in the SPPARCS study who 
were free of known CHF or previous myocardial infarction. SP-
PARCS is a community-based cohort study in residents of Sonoma, 
California that are > 55 years. Medical history and 12-lead ECGs 
were obtained every 2 years for up to 6 years of follow-up. LBBB 
at enrollment or year 2 was considered “baseline” and assessed as 
a predictor of CHF and cardiovascular death ascertained at years 
4 and 6.
Results: The prevalence of LBBB at baseline was 2.5% (n = 42). 
During 6 years of follow-up, 70 (4.8%) people developed new 
CHF. Incidence of CHF was higher in patients with LBBB than in 
participants without LBBB. This association persisted after control-
ling for potential confounders (odds ratio (OR): 2.85; 95% confi-
dence interval (CI): 1.01 - 8.02; P = 0.047). A higher mortality from 
cardiovascular diseases was also found in participants with LBBB 
after adjusting for potential confounders (OR: 2.35, 95%CI: 1.02 - 
5.41; P = 0.044).
Conclusions: LBBB in the absence of a clinically detectable heart 
disease is associated with new-onset CHF and death from cardio-
vascular diseases. Further study is warranted to determine if addi-
tional diagnostic testing or earlier treatment in patients with asymp-
tomatic LBBB can decrease cardiovascular morbidity or mortality.
Keywords: Bundle-branch block; Heart failure; Mortality; Risk 
factors
Introduction
The electrocardiogram (ECG) is one of the most commonly 
ordered tests in everyday clinical practice. Consequently, 
detecting subjects with abnormalities of the cardiac conduc-
tion system such as left bundle branch block (LBBB) in the 
absence of clinically detectable heart disease is relatively 
common [1, 2].
It is not clear what cardiovascular morbidities to expect, 
if any, when asymptomatic patients develop LBBB. Previous 
studies investigating cardiac conduction abnormalities have 
focused mainly on survival of patients with LBBB in the 
setting of ischemic heart disease and acute coronary artery 
disease [3-7]. The significance of LBBB has not been well 
studied in subjects without myocardial infarction or preex-
isting heart failure. Therefore, we sought to characterize the 
long-term prognostic implication of asymptomatic LBBB on 
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congestive heart failure (CHF) development and death from 
cardiovascular diseases in a large generally healthy popula-
tion.
 
Methods
We analyzed data from the Study of Physical Performance 
and Age-related Changes in Sonomans (SPPARCS) Project. 
The project is a community based prospective longitudinal 
cohort study of physical activity and physical fitness in peo-
ple 55 years or older that live in Sonoma, CA or in the city’s 
vicinity. The methods of recruitment and the representative 
of the sample to its target population have been described 
[8]. A community-based census identified 3,057 age eligible 
individuals. Eventually 2,092 people enrolled in the study 
and completed the baseline interview. Among these partici-
pants, 1,688 people with no history of CHF or myocardial 
infarction were recruited for this study.
Enrolled participants underwent detailed standardized 
interviews and filled out standardized questionnaires. These 
included detailed questions about medical conditions. Iden-
tified medical conditions were ascertained by physician’s 
diagnosis and medical treatment, 12 lead ECG testing was 
done at regular 2 year intervals. Patients were followed for 
4 total assessments unless they died, left the study, or were 
lost to follow-up. The primary outcomes of the current study 
were incident CHF and death from cardiovascular diseases. 
Cardiovascular deaths were those included in International 
Classification of Disease 9th Revision (ICD9) codes 394 
through 448. CHF and cardiovascular death were ascertained 
at the 3rd and 4th assessments.
LBBB was defined as (1) QRS duration > 120 ms, (2) 
PQ interval > 120 ms, (3) predominantly upright complexes 
with slurred R waves in leads I, V5, and V6, and (4) small 
of absent R waves in leads V1 and V2. The other predictors 
examined were demographic and medical characteristics in-
cluding age, gender, atherosclerosis, hypertension, diabetes, 
kidney disease, and COPD at each time interval. Age was re-
corded as a continuous variable and all the other risk factors 
were recorded as a yes/no dichotomous variables.
The statistical analyses were performed using SPSS ver-
sion 16. Categorical data were compared using the χ2 test, 
and continuous data were compared using ANOVA. Logistic 
regression analyses were used to determine the relationship 
of LBBB with CHF and cardiovascular death in both bivari-
ate models and multivariable analysis controlling for all po-
tential confounders. A value of P < 0.05 was considered to 
be statistically significant. The study was approved by the 
Committee on Human Research at the University of Cali-
fornia, San Francisco and the Committee for protection of 
Human Subjects at the University of California, Berkeley. 
Written informed consent was obtained from all subjects in 
the study prior to data collection. No extramural funding was 
used to support this work. The authors are solely responsible 
for the design and conduct of this study; all study analyses, 
the drafting and editing of the paper and its final contents.
 
Results
Characterization of participants
A total of 1,688 individuals aged 55 years or older were 
enrolled and followed for at least 6 years. Shown in Figure 
1, the prevalence of LBBB at baseline was 2.5% (n = 42). 
Table1. Baseline Characteristic of the Study Population According to Their ECG LBBB Diagnosis
* P < 0.05; COPD: Chronic obstructive pulmonary disease.
Characteristic With LBBB(n = 42)
Without LBBB
(n = 1,646)
Total
(n = 1,688)
Male, n (%) 17 (40.5) 669 (40.6) 686 (40.6)
Age, y (mean ± SD) 74.0 ± 8.4* 69.2 ± 8.3 69.4 ± 8.3
Atherosclerosis, n (%) 13 (31.0)* 268 (16.3) 281 (16.6)
Hypertension, n (%) 23 (54.8) 720 (43.7) 743 (44.0)
Diabetes, n (%) 4 (9.5) 101 (6.1) 105 (6.2)
Kidney disease, n (%) 2 (4.8) 44 (2.7) 46 (2.7)
COPD, n (%) 2 (4.8) 194 (11.8) 196 (11.6)
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Subjects with LBBB were older (mean age 74.0 ± 8.4 years 
vs. 69.2 ± 8.3 years, P < 0.001) and reported a greater preva-
lence of atherosclerosis (31.0% vs. 16.3%, P < 0.05). The 
baseline characteristics of both groups are shown in Table 1.
Congestive heart failure development
During follow up, 70 (4.8%) people of the study population 
developed CHF. In bivariate analysis, baseline LBBB was 
associated with a 3.64 greater odds of developing CHF (95% 
confidence interval (CI): 1.37, 9.71; P = 0.006). In multi-
variable logistic regression analysis adjusting for potential 
confounders, participants with baseline LBBB remained 
nearly three (2.85) times more likely to develop CHF (Table 
2). Other risk factors for the development of CHF identified 
in this model were age, atherosclerosis, diabetes, and COPD.
Mortality
Of a total of 351 (20.1%) deaths from all causes that occurred 
during follow-up, 133 (7.9%) were listed as cardiovascular 
diseases (Table 3). Unadjusted mortality rate from cardio-
vascular and cardiac diseases was higher among patients 
with LBBB compared to those without LBBB. In bivariate 
analysis, patients with LBBB had 4.34 times greater odds of 
dying from cardiovascular disease (95% CI: 2.02, 8.89; P 
= 0.001; Fig. 2). This association remained significant after 
controlling for other potential confounders (Table 2). Other 
independent risk factors for cardiovascular death in our pop-
ulation were age, gender, atherosclerosis, and hypertension.
Discussion
  
Individuals with asymptomatic LBBB had an increased in-
cidence of CHF and death from cardiovascular disease. It is 
unclear if LBBB is a marker of subclinical cardiac disease 
that manifests overtly later, or if LBBB is intrinsically del-
eterious, causing CHF and cardiovascular death.
The association between LBBB and cardiovascular mor-
bidity has been investigated, but given conflicting results, 
controversy regarding the prognosis of LBBB persists. Fahy 
observed a higher rate of developing overt cardiovascular 
disease among people with isolated LBBB [2]. However, he 
did not specify the type of cardiovascular diseases. In the 
Framingham Study, newly acquired LBBB was associated 
with an advanced underlying cardiac abnormality including 
symptomatic hypertensive or ischemic heart disease [9]. On 
the other hand, Rotman did not observe any significant dif-
ference in incident cardiovascular morbidity among subjects 
Table2. Multivariable Logistic Analysis of LBBB as a Predictor of Incident CHF and Cardiovascular Death
LBBB: Left bundle branch block; COPD: Chronic obstructive pulmonary disease; CHF: Congestive heart failure; CHF identified in 
this model were age, atherosclerosis, diabetes, and COPD.
Characteristics
Incident CHF
Cumulative Incidence Ratio
Cardiovascular Death
Cumulative Incidence Ratio
(95% CI) P (95% CI) P
Demographic characteristics
Age 1.06 (1.02 - 1.09) 0.001 1.15 (1.12 - 1.18) 0.000
Male gender 1.11 (0.67 - 1.85) 0.629 1.64 (1.11 - 2.44) 0.014
Medical/environmental history
LBBB 2.85 (1.01 - 8.02) 0.047 2.35 (1.02 - 5.41) 0.044
Atherosclerosis 3.05 (1.79 - 5.19) 0.000 2.66 (1.75 - 4.03) 0.000
Hypertension 1.68 (0.99 - 2.84) 0.051 1.57 (1.05 - 2.35) 0.027
Diabetes 2.31 (1.09 - 4.91) 0.029 1.18 (0.59 - 2.37) 0.644
Kidney Disease 1.15 (0.26 - 5.18) 0.852 1.95 (0.73 - 5.18) 0.182
COPD 2.21 (1.14 - 4.26) 0.018 1.07 (0.60 - 1.88) 0.824
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with LBBB [10]. Notably, participants in that study were not 
free of cardiovascular disease. In a population based study, 
Erikson found a higher incidence of CHF among men with 
bundle branch block [11]. Notably, the studied population 
was not free of myocardial infarction or heart failure, women 
were not included, and this association was found in patients 
with any type of bundle branch block.
One might speculate on a possible causal role in which 
LBBB may lead to CHF. It is believed that right-to left ven-
tricle endocardial activation that occurs in LBBB results in 
Table3. Causes of Death of the Study Population
a: Percent of category deaths.
Cause of death (n = 362) Number (%)
Cardiovascular 134 (37.1)
Cardiac 97 (72.4) a
Atherosclerotic cardiovascular disease 14 (14.4) a
Cardiac arrest 2 (2.1)
Congestive heart failure 23 (23.7)
Coronary artery disease 7 (7.2)
Heart disease 51 (52.6)
Noncardiac 37 (27.6)
Stroke 34 (91.9) a
Other (aortic aneurysms) 3 (8.1)
Non-cardiovascular 228 (62.9)
Figure 2. Kaplan-Meier survival curve showing the effects of left bundle branch block on cardiovascular mortality by age 
(P < 0.05).
260                                                                                                                                                                                                                                                                                                                                                                                                                                             261
Cardiol Res  •  2012;3(6):258-263   LBBB, Heart Failure and Mortality
Articles © The authors   |   Journal compilation © Cardiol Res and Elmer Press™   |   www.cardiologyres.org
left ventricular dyssynchrony, compromising systolic and 
diastolic function [12]. This dyssynchrony may also trigger 
remodeling processes that lead to progressive left ventricu-
lar dysfunction [13]. Alternatively, bundle branch block has 
been shown to be associated with a degenerative process of 
both the conduction system and the myocardium itself which 
could lead to various dysrhythmias and conduction distur-
bances as well as impair myocardial function [11].
The association between LBBB and mortality has been 
previously suggested by a few studies in the literature [14, 
15]. In community-based studies, all-cause and cardiovas-
cular mortality was higher among patients with asymptom-
atic LBBB [2, 9, 14]. In this study, we looked at different 
classifications of cardiovascular death and the association 
of isolated LBBB and cardiovascular mortality in an older 
population free of any known previous CHF or myocardial 
infarction based on very detailed interviews and question-
naires. Our results suggest that LBBB, in the absence of 
overt clinical heart disease, is significantly associated with 
death from cardiovascular diseases. The nature of this as-
sociation remains unclear. Whether LBBB is yet another 
marker that reflects a generalized physiological aging pro-
cess (for example, diabetes) or is more directly and causally 
involved in the pathway to cardiovascular death remains un-
answered. Although we controlled for cardiovascular disease 
risk factors including diabetes, coronary artery disease, and 
hypertension, the possibility that cardiovascular disease risk 
are more severe in patients with LBBB than in the normal 
population may account for the higher mortality rate found 
in patients with LBBB.
In view of our findings and those of others, it appears 
reasonable to question whether the finding of asymptom-
atic LBBB should prompt further diagnostic testing or early 
treatment that might prevent CHF and cardiovascular mor-
bidity. Currently, neither further testing nor treatment is 
recommended when asymptomatic LBBB is found. Other 
studies would be helpful to evaluate possible therapeutic op-
tions. The benefit of early treatment of diagnosed CHF has 
been previously shown by other studies in patients following 
myocardial infarction [16]. Heart failure treatment may also 
prove to be beneficial in patients with asymptomatic LBBB 
who have yet to develop CHF, possibly by staving off the 
progression to symptomatic CHF.
Limitations
Several limitations exist to our study. First, the assessment 
of medical conditions was based on interviews with the 
patient rather than independent adjudication. For example, 
participants may have been unaware of underlying CHF or 
may have failed to recollect the diagnosis when complet-
ing the baseline questionnaire. Second, our assessment of 
LBBB was based on one to two 12 lead ECGs done over 
2 years. Therefore, some participants may have had inter-
mittent LBBB that was not detected. However, this likely 
would have resulted in decreased power and should not have 
resulted in false positive associations.
Conclusions
Our data indicate that patients with asymptomatic LBBB are 
at increased risk of developing CHF and of dying from car-
diovascular diseases. Further study is warranted to determine 
if more diagnostic testing or earlier treatment in patients with 
asymptomatic LBBB can decrease cardiovascular morbidity 
or mortality.
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